Ivan Suner, MD
Ophthalmology · Tampa, FLNPI 1164522793
Payments from drug & device makers
Across 1,038 payments — averaging $3581.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3.1M
- Apellis Pharmaceuticals, Inc.$215K
- Genentech USA, Inc.$153K
- Novartis$105K
- Regeneron Healthcare Solutions, Inc.$56K
- Eyepoint US, Inc.$35K
- plus $75K from 29 others
Across 22 payments — averaging $2353.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$31K
- Ocular Therapeutix, Inc.$11K
- Regeneron$6K
- F. Hoffmann-la Roche AG$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 440 | $3,078,632 |
| Apellis Pharmaceuticals, Inc. | 142 | $215,286 |
| Genentech USA, Inc. | 167 | $152,987 |
| Novartis | 30 | $105,392 |
| Regeneron Healthcare Solutions, Inc. | 62 | $55,632 |
| Eyepoint US, Inc. | 11 | $35,376 |
| Ocular Therapeutix, Inc. | 24 | $29,765 |
| ANI Pharmaceuticals, Inc. | 3 | $13,167 |
| Regeneron | 28 | $10,322 |
| AbbVie(2 entities) | 22 | $6,163 |
| Bausch & Lomb Americas Inc. | 20 | $4,462 |
| Astellas Pharma US Inc | 8 | $3,292 |
| F. Hoffmann-la Roche AG | 2 | $1,722 |
| Thrombogenics, Inc. | 1 | $1,250 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $830 |
| Alimera Sciences, Inc. | 20 | $785 |
| Amgen | 5 | $564 |
| Harrow Eye, LLC | 6 | $468 |
| Alcon | 4 | $325 |
| Notal Vision, Inc. | 2 | $323 |
| Coherus Oncology, Inc. | 6 | $227 |
| Sight Sciences, Inc. | 1 | $149 |
| NEW World Medical,inc. | 1 | $142 |
| Sandoz | 5 | $137 |
| Biogen | 3 | $133 |
| Immunocore Limited | 1 | $125 |
| Dompe US, Inc. | 1 | $122 |
| Cardinal Health 108 LLC | 1 | $75 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Sun Pharmaceutical Industries Inc. | 2 | $47 |
| Samsara Vision | 1 | $32 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $22 |
| Astellas Pharma Global Development | 1 | $16 |
| Oyster Point Pharma, Inc. | 1 | $15 |
How this compares
$3,718,080 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Tampa
- Pedram HamrahTampa$2.2M
- Thomas NewsomTampa$1.5M
- Courtney BoveeTampa$884K
- Ashley CraneTampa$491K
- Don PerezTampa$367K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.